Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.